NFE2L2 and in situ carcinoma: It reactivated the Nrf2 pathway (36), most likely inhibited by ERS (44) and consequently reduced inflammatory response to CIS (49) and apoptosis, which is consistent with previous reports of ERS inhibition and anti-apoptotic (19, 50, 51) as well as the anti-inflammatory activity of CHA (52,53,54).